Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
This study is ongoing, but not recruiting participants.
Study NCT01252940
Information provided by Gilead Sciences
First Received on December 1, 2010.
Last Updated on April 19, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
